Melody Mazon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melody Mazon has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Madeleine Carreau
Centre Hospitalier Universitaire de Québec-Université Laval, CHUL, 2705 Boul. Laurier, RC-9800, Quebec, QC, G1V 4G2, Canada.
2 shared publications - Delphine Masi
CHU de Québec Research Center, 2705 Boulevard Laurier, RC-9800, Québec, QC G1V 4G2, Canada
1 shared publication - Fabrice Mac-Way
CHU de Québec‐Université Laval Research Centre Quebec Quebec Canada
1 shared publication Jacinthe Julien
1 shared publicationRoth-Visal Ung
1 shared publicationSarah-Kim Bisson
1 shared publication
Latest Publications
- 11 July 2017
- Published by Bioscientifica in Bone Abstracts
Altered bone metabolism in Fanconi anemia results from defective mesenchymal stem cell differentiation
Fanconi anemia (FA) is a rare genetic disease associated with a progressive decline in hematopoietic stem cells leading to bone marrow failure. FA is also characterized by various developmental defects including short stature and skeletal malformations of the upper and lower limbs. Indeed, more than half of children affected with FA have radial-ray abnormalities with a tendency to early osteoporosis and osteopenia. However, the underlying mechanisms leading to bone defects in FA remains elusive. Objective: We aimed to determine the mechanism leading to altered bone development and metabolism in FA. Methods: Bone structure, mass and mineral content were evaluated using μCT-scan analyses of tibias from FancC−/− and wild-type mice. Bone’s resorption activity was determined with tartrate-resistant acid phosphatase staining. To evaluate skeletal maturation, alizarin red and Alcian blue double staining were performed on mouse embryos (E15.5 to 19.5 dpc). To assess mesenchymal stem cell differentiation ability, in-vitro cultures and qPCR analysis of bone marrow stromal cells were performed. Results: Our results show that FancC−/− mice present a 15% decrease in bone mineral content, reduced cortical thickness and diameter combined with a 15% reduction of the bone marrow area. FancC−/− mice also present elevated tartrate-resistant acid phosphatase staining as compared to wild-type littermates. In addition, FancC−/− embryos show abnormal skeletal development indicated by decreased bone length and mineralization. Using in vitro studies, we found that FancC−/− mesenchymal stem cells (MSC) have reduced osteoblastic differentiation capabilities and engraftment potential in favor of adipogenesis. Accordingly, FA-defective MSC present altered gene expression profiles of differentiation markers. Conclusion: Together, our results suggest that defective bone metabolism in FA occurs in utero and results from altered MSCs function. These results provide, for the first time, valuable insights into the mechanism involved in FA developmental defects. Disclosure The authors declared no competing interests.
- 11 July 2017
- Published by Bioscientifica in Bone Abstracts
Altered bone metabolism in Fanconi anemia results from defective mesenchymal stem cell differentiation
Fanconi anemia (FA) is a rare genetic disease associated with a progressive decline in hematopoietic stem cells leading to bone marrow failure. FA is also characterized by various developmental defects including short stature and skeletal malformations of the upper and lower limbs. Indeed, more than half of children affected with FA have radial-ray abnormalities with a tendency to early osteoporosis and osteopenia. However, the underlying mechanisms leading to bone defects in FA remains elusive. Objective: We aimed to determine the mechanism leading to altered bone development and metabolism in FA. Methods: Bone structure, mass and mineral content were evaluated using μCT-scan analyses of tibias from FancC−/− and wild-type mice. Bone’s resorption activity was determined with tartrate-resistant acid phosphatase staining. To evaluate skeletal maturation, alizarin red and Alcian blue double staining were performed on mouse embryos (E15.5 to 19.5 dpc). To assess mesenchymal stem cell differentiation ability, in-vitro cultures and qPCR analysis of bone marrow stromal cells were performed. Results: Our results show that FancC−/− mice present a 15% decrease in bone mineral content, reduced cortical thickness and diameter combined with a 15% reduction of the bone marrow area. FancC−/− mice also present elevated tartrate-resistant acid phosphatase staining as compared to wild-type littermates. In addition, FancC−/− embryos show abnormal skeletal development indicated by decreased bone length and mineralization. Using in vitro studies, we found that FancC−/− mesenchymal stem cells (MSC) have reduced osteoblastic differentiation capabilities and engraftment potential in favor of adipogenesis. Accordingly, FA-defective MSC present altered gene expression profiles of differentiation markers. Conclusion: Together, our results suggest that defective bone metabolism in FA occurs in utero and results from altered MSCs function. These results provide, for the first time, valuable insights into the mechanism involved in FA developmental defects. Disclosure The authors declared no competing interests.
- Open Access
Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?
Dickkopf-1 (DKK1) is a secreted Wnt/β-catenin pathway antagonist involved in embryogenesis. It was first described 25 years ago for its function in head induction and limb morphogenesis. Since then, this protein has been widely studied in the context of active Wnt/β-catenin signalling during cellular differentiation and development. Dysregulation of DKK1 has been associated with bone pathologies and has now emerged as a potential biomarker of cancer progression and prognosis for several types of malignancies. Reducing the amount of circulating DKK1 may reveal a simple and efficient strategy to limit or reverse cancer growth. This review will provide an overview of the role of Dickkopf-1 in cancer and explore its potential use as a biomarker and therapeutic target.
Open AccessModulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?
Dickkopf-1 (DKK1) is a secreted Wnt/β-catenin pathway antagonist involved in embryogenesis. It was first described 25 years ago for its function in head induction and limb morphogenesis. Since then, this protein has been widely studied in the context of active Wnt/β-catenin signalling during cellular differentiation and development. Dysregulation of DKK1 has been associated with bone pathologies and has now emerged as a potential biomarker of cancer progression and prognosis for several types of malignancies. Reducing the amount of circulating DKK1 may reveal a simple and efficient strategy to limit or reverse cancer growth. This review will provide an overview of the role of Dickkopf-1 in cancer and explore its potential use as a biomarker and therapeutic target.